Monitoring Minimal Residual Disease in Acute Myeloid Leukemia Using Genomic or cfDNA with MyMRD®, a Targeted NGS Panel

Zhiyi Xie, Lisa Chamberlain,Andrew Carson, Veronika Atkinson,Valerie McClain, James Sprague,Ogeen Kiya, Peng Xia, Wenli Huang,Bradley Patay, Martin Blankfard,Jeffrey E Miller

BLOOD(2018)

引用 0|浏览2
暂无评分
摘要
Acute myeloid leukemia (AML) is a genetically and phenotypically heterogeneous disorder. Precision therapies for AML have been developed that target specific driver mutations. The efficacies of these therapies are variable, making it critical to determine successful therapies prior to patient relapse. For patients achieving a first complete remission, minimum residual disease (MRD) is an important prognostic factor, as MRD may provide a powerful and timely tool to evaluate therapeutic efficacy. There is a growing demand that new and promising drugs are approved as quickly as possible and accelerated approvals will require biomarker surrogate endpoints, such as MRD, rather than long-term survival endpoints.
更多
查看译文
关键词
acute myeloid leukemia,myeloid leukemia,cfdna,minimal residual disease
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要